RAP 0.00% 20.5¢ raptor resources limited

Ann: ResApp Announces Expanded Research Collaboration with MGH, page-4

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 113 Posts.
    ASX / MEDIA RELEASE
    ResApp Announces Expanded Research Collaboration with
    Massachusetts General Hospital
    Brisbane, Australia, 10 January 2017 -- ResApp Health Limited (ASX: RAP), the
    developer of smartphone medical applications for the diagnosis and management of
    respiratory disease, today announced that it has entered into a two-year expanded
    research collaboration with Massachusetts General Hospital (MGH) alongside MGH’s
    participation in ResApp’s SMARTCOUGH-C study. Working together, ResApp and
    MGH will perform additional analysis of the SMARTCOUGH-C study data, use the
    SMARTCOUGH-C dataset to investigate the state of respiratory disease clinical
    practice today and evaluate the efficacy of ResApp’s cough-based diagnostic test in
    additional respiratory disease indications.
    MGH is a 999-bed academic medical centre located in Boston, Massachusetts. MGH
    has been named the number one healthcare organization for research by the Nature
    Index which tracked the number of articles published in high-impact research
    journals from February 2015 to January 2016 and has been among the top hospitals
    each year on the U.S. News & World Report list of “America’s Best Hospitals.”
    Dr. Peter Moschovis M.D., MPH will lead the team at MGH. Dr. Moschovis undertook
    his specialist training at Harvard Medical School and has a joint appointment in
    paediatrics and pulmonary/critical care at MGH. Dr. Moschovis is a global health
    researcher in the Division of Global Health at MGH.
    “We are delighted to expand our relationship with Dr. Moschovis and MGH beyond
    the SMARTCOUGH-C study to diagnose additional diseases and to evaluate clinical
    practices. The more broadly and effectively we apply ResApp’s technology with our
    partners, the more rapidly we will integrate our diagnostic test into current clinical
    practice,” said Tony Keating, CEO and Managing Director of ResApp Health.
    - ENDS –
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.